Lecanemab Homecare Service

University College London Hospitals NHS Foundation Trust (UCLH) is conducting an open procurement process to secure a homecare service provider for the direct supply and administration of Lecanemab (Leqembi) in patients' homes. The service targets adult patients with mild cognitive impairment and mild dementia due to Alzheimer's disease, specifically apolipoprotein E ε4 heterozygotes or non-carriers. The tender, titled "Lecanemab Homecare Service," falls under the pharmacy services industry category and covers the UK location, with specific delivery addresses in London (UKI3).

The process is currently in the tender stage, with the deadline for submissions being 26th March 2025, and the award period starting on 19th February 2025. The overall contract value is projected at £816,000, with a contract duration of 720 days. Details and submissions are to be handled electronically and in writing via the specified submission portal.

This tender provides significant opportunities for private homecare providers within the healthcare sector, particularly those experienced in managing home-based administration of medication for Alzheimer’s patients. Given the highly specialised nature of the service, businesses with expertise in pharmacy services, homecare deliveries, and patient healthcare management will be well-suited to compete. The successful provider will not only benefit from a substantial contract with a renowned NHS Trust but also from the potential long-term partnership and enhanced reputation within the healthcare services industry.